Articles tagged with Vascular Endothelial Growth Factor
Researchers discovered that VEGF promotes the growth and survival of malignant tumor cells, affecting a wide range of cancers. The study found that inhibiting VEGF's effects can slow or halt tumor growth and is expected to improve treatment outcomes for some patients.
Mutations of the Lkb1 gene cause Peutz-Jeghers syndrome, a disorder characterized by polyps in the intestines and increased risk for cancerous tumors. Researchers found that Lkb1 regulates the formation of heart and blood vessels in embryos.
A new study by UCSF researchers found that delivering the VEGF growth factor into mice with coronary heart disease prompted the growth of blood vessels in damaged heart tissue without causing side effects. This approach could lead to a treatment strategy for severe coronary heart disease that has been met with setbacks.
A follow-up study of the VEGF in Ischemia for Vascular Angiogenesis (VIVA) trial found that gene therapy did not increase the risk of cancer or adverse events in patients with severe angina. The results showed a lower rate of adverse events in patients receiving the high-dose VEGF, and encouraging reductions in chest pain after one year.
A new study from the University of California, San Francisco, suggests that stimulating blood vessel growth with VEGF may help repair stubbornly non-healing fractures. Researchers found that injecting VEGF into broken mouse legs promoted bone growth and increased expression of genes necessary for osteoblast formation.
Researchers at UCSD School of Medicine have discovered a defensive molecular mechanism launched by the body to protect against oxygen deprivation on the heart. HIF and VEGF, two angiogenesis genes, are activated in response to ischemia or infarction, attempting to increase decreasing blood flow.
A new anti-angiogenesis drug delivered as a nose drop has shown promising results in treating AIDS-related Kaposi's Sarcoma. The study found a major response rate of 36% among patients, with some experiencing complete remission and others experiencing stabilization or regression of their disease for several weeks after stopping treatment.
Researchers at Johns Hopkins and CIBA Vision Corp. have identified a natural chemical substance responsible for blinding blood vessel growth in patients with diabetic retinopathy. The study found that blocking this substance can completely stop abnormal vessel growth, offering new potential treatments for the condition.
Researchers at UCSF and Regeneron Pharmaceuticals have found that the protein angiopoietin-1 (Ang1) can restore leaky vessels to normal, block leakage effects of substances, and complement VEGF's growth-promoting action. This discovery holds strong promise for treating chronic inflammatory diseases and promoting healthy blood vessel gr...
Scientists have found a possible way to induce new blood vessels without gene therapy, by lowering an individual's heart rate, according to a University of Iowa Health Care study.
Researchers found that blocking VEGF can significantly increase the effectiveness of radiation therapy against various types of cancer. The combination of anti-VEGF and radiation resulted in greater tumor reduction and slowed re-growth, even with minimal added toxicity.
Scientists have identified a drug that completely stops the growth of abnormal blood vessels on or beneath the retinas of laboratory mice, potentially preventing vision loss. The drug, PKC 412, has shown promising results in halting abnormal vessel growth by up to 100%, with no apparent adverse effects on normal blood vessels.
A University of Michigan team discovered that vascular endothelial growth factor (VEGF) helps blood vessels survive and proliferate in the face of nutrient depletion. This mechanism is thought to support tumor growth, leading researchers to explore strategies for inhibiting VEGF to starve tumors.
Researchers at Harvard Medical School found that a protein wireing the developing brain also prevents nerve cells from entering off-limits areas, and plays a role in blood vessel formation. This convergence of two processes may lead to new insights into cancer research and embryology.
Scientists at Max Planck Institute have developed a non-invasive method to supply diseased hearts with vessel growth promoting factors, using microscopic beads that slowly release growth factor over 7 days. The treatment is suitable for small vessels but not large stenosing coronary vessels.
Scientists have identified a new factor regulating lymphatic vessel growth, which may lead to ways of repairing damaged vessels and better understanding of certain types of cancer. The discovery of VEGF-C could also improve healing after lymph node removal in breast cancer surgery or prevent tumors affecting the lymphatic system.
NeXstar Pharmaceuticals has created an aptamer-based diagnostic assay for its VEGF inhibitor, enhancing cancer treatment possibilities. The ELONA system uses an aptamer to detect small amounts of clinically important substances, overcoming limitations of traditional antibodies in diagnostic assays.